Physician investment in startup device companies: debunking the myths.

نویسنده

  • Alice G Gosfield
چکیده

Physician entrepreneurship is on the rise; and investment by physicians in startup device companies is one manifestation of it. At the same time, there is increasing concern about potential conflicts of interest in physician business interests, given their fiduciary responsibility to their patients. There are multiple forms such investment can take. The Stark and anti-kickback statutes are relevant to investment in companies that do business with the federal programs. Many physicians are confused about the distinctions between these two statutes and their different requirements. This article elucidates these distinctions, describes a continuum of safety associated with such investment, and offers some practical tips for those considering or involved in such arrangements.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Debunking some myths and misconceptions about indexing

One of the most persistent myths in the investment industry is that it makes sense to use an index strategy in efficient markets, for instance with large-capitalization stocks, but to use an active strategy in inefficient segments. It’s important to note that the term inefficient is often used to refer to informational inefficiencies. But investors must also consider the full spectrum of costs ...

متن کامل

Developed Technologies and Active Startup Companies in Dealing with COVID-19 Pandemic in Iran

On February 2020, Iran reported its first confirmed cases of infections COVID-19 pandemic and since than its effects have been widely spread across in Iran and worldwide. The devastating consequences of the COVID-19 pandemic showed that science and technologies play an important role in ensuring national security and social stability is such crises and we must learn from this event to better pr...

متن کامل

Drug price reform in the UK: debunking the myths.

The OFT report into the Pharmaceutical Price Regulation Scheme (PPRS) called for reform of the scheme, replacing existing profit and price controls with a system of value-based pricing (VBP). The report argued that VBP would be much more effective than the current PPRS both at providing value for money for the NHS and giving pharmaceutical companies the right incentives to invest in drugs in th...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Journal of medical practice management : MPM

دوره 23 3  شماره 

صفحات  -

تاریخ انتشار 2007